CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 23, 2015
Result type: Reports
Project Number: SR0454-000
Product Line: Reimbursement Review

Generic Name: Elbasvir/grazoprevir

Brand Name: Zepatier

Manufacturer: Merck Canada Inc.

Therapeutic Area: Hepatitis C, chronic

Indications: Hepatitis C, chronic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 19, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions